Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2014 1
2015 3
2016 2
2017 3
2018 7
2019 3
2020 4
2021 5
Text availability
Article attribute
Article type
Publication date

Search Results

27 results
Results by year
Filters applied: . Clear all
Page 1
Selective targeting of nanomedicine to inflamed cerebral vasculature to enhance the blood-brain barrier.
Marcos-Contreras OA, Greineder CF, Kiseleva RY, Parhiz H, Walsh LR, Zuluaga-Ramirez V, Myerson JW, Hood ED, Villa CH, Tombacz I, Pardi N, Seliga A, Mui BL, Tam YK, Glassman PM, Shuvaev VV, Nong J, Brenner JS, Khoshnejad M, Madden T, Weissmann D, Persidsky Y, Muzykantov VR. Marcos-Contreras OA, et al. Among authors: brenner js. Proc Natl Acad Sci U S A. 2020 Feb 18;117(7):3405-3414. doi: 10.1073/pnas.1912012117. Epub 2020 Jan 31. Proc Natl Acad Sci U S A. 2020. PMID: 32005712 Free PMC article.
Targeting drug delivery in the vascular system: Focus on endothelium.
Glassman PM, Myerson JW, Ferguson LT, Kiseleva RY, Shuvaev VV, Brenner JS, Muzykantov VR. Glassman PM, et al. Among authors: brenner js. Adv Drug Deliv Rev. 2020;157:96-117. doi: 10.1016/j.addr.2020.06.013. Epub 2020 Jun 21. Adv Drug Deliv Rev. 2020. PMID: 32579890 Free PMC article. Review.
Systems approaches to design of targeted therapeutic delivery.
Myerson JW, Brenner JS, Greineder CF, Muzykantov VR. Myerson JW, et al. Among authors: brenner js. Wiley Interdiscip Rev Syst Biol Med. 2015 Sep-Oct;7(5):253-65. doi: 10.1002/wsbm.1304. Epub 2015 May 6. Wiley Interdiscip Rev Syst Biol Med. 2015. PMID: 25946066 Free PMC article. Review.
Endothelial nanomedicine for the treatment of pulmonary disease.
Brenner JS, Greineder C, Shuvaev V, Muzykantov V. Brenner JS, et al. Expert Opin Drug Deliv. 2015 Feb;12(2):239-61. doi: 10.1517/17425247.2015.961418. Epub 2014 Nov 14. Expert Opin Drug Deliv. 2015. PMID: 25394760 Free PMC article. Review.
However, to maximize the chances of creating products that reach patients, nanomedicine engineers and clinicians must work together and use each disease's need specification to guide the design of practical and effective nanomedicine agents....
However, to maximize the chances of creating products that reach patients, nanomedicine engineers and clinicians must work together and use …
Unintended effects of drug carriers: Big issues of small particles.
Parhiz H, Khoshnejad M, Myerson JW, Hood E, Patel PN, Brenner JS, Muzykantov VR. Parhiz H, et al. Among authors: brenner js. Adv Drug Deliv Rev. 2018 May;130:90-112. doi: 10.1016/j.addr.2018.06.023. Epub 2018 Jul 3. Adv Drug Deliv Rev. 2018. PMID: 30149885 Free PMC article. Review.
The Nano-War Against Complement Proteins.
Wang Z, Brenner JS. Wang Z, et al. Among authors: brenner js. AAPS J. 2021 Sep 10;23(5):105. doi: 10.1208/s12248-021-00630-9. AAPS J. 2021. PMID: 34505951 Free PMC article. Review.
Here, we review how complement achieves its blockade of nanomedicine, which nanocarrier materials properties best avoid complement, and current and future strategies to control complement to unleash nanomedicine's potential....
Here, we review how complement achieves its blockade of nanomedicine, which nanocarrier materials properties best avoid complement, and curr …
Nanomedicine to fight infectious disease.
Rubey KM, Brenner JS. Rubey KM, et al. Among authors: brenner js. Adv Drug Deliv Rev. 2021 Oct 8;179:113996. doi: 10.1016/j.addr.2021.113996. Online ahead of print. Adv Drug Deliv Rev. 2021. PMID: 34634395 Review.
Using selective lung injury to improve murine models of spatially heterogeneous lung diseases.
Paris AJ, Guo L, Dai N, Katzen JB, Patel PN, Worthen GS, Brenner JS. Paris AJ, et al. Among authors: brenner js. PLoS One. 2019 Apr 3;14(4):e0202456. doi: 10.1371/journal.pone.0202456. eCollection 2019. PLoS One. 2019. PMID: 30943189 Free PMC article.
Current mouse models that aim to mimic ARDS generally produce diffuse injuries that cannot reproducibly generate ARDS's regional heterogeneity. This deficiency prevents the evaluation of how well therapeutic agents reach the most injured regions and precludes many regenera …
Current mouse models that aim to mimic ARDS generally produce diffuse injuries that cannot reproducibly generate ARDS's regional hete …
27 results